Homeopathic Add-On for Allergic Rhinitis: A Clinical Study

Phase 2

Recruiting

• Conditions: Health Condition 1: J309- Allergic rhinitis, unspecified

• Registration Number: CTRI/2023/12/060638
• Lead Sponsor: All India Institute of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Age > 18 years

2. Patients having moderate to severe Allergic Rhinitis as per ARIA guidelines

3. Atopic: reactive to inhaled allergens with positive skin test results

4. More than 1 year history of AR.

Exclusion Criteria

Any other types of chronic rhinitis

History of anaphylactic reactions

Moderate to severe atopic dermatitis

Symptoms of asthma in accordance with the GINA criteria with more than one of the following: (1) occurrence of asthma symptoms more than twice per week, (2) any night waking due to asthma, (3) reliever (beta-2-sympathomimeticdrug) needed more than twice per week, except for reliever taken before exercise, (4) activity limitation due to asthma

Renal insufficiency (serum creatinine concentration above (0.6–1.4 mg/dl or 50–130 µmol/l) measured within the last 16 weeks;

Current daily use of topical or systemic corticosteroids;

Allergen-specific immunotherapy used currently or within the past 3 years;

Homeopathic therapy used currently or within the past 6 weeks;

Recent (the past 6 weeks) use of other complementary and integrative medicine treatments for AR

Alcohol addiction; pregnancy or breastfeeding;

Serious acute or chronic organic diseases or serious mental disorder;

Severely immuno-compromised patients for example patients with history of HIV infection, patients with solid organ transplantation or bone marrow transplantation, patients receiving chemotherapy/radiotherapy, patients with primary immunodeficiency.

Have cardiovascular disease or severe haematological illness like Sickle cell disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total nasal symptom scores (TNSS)Timepoint: 0,2, 4, 8, and 12 weeks

Secondary Outcome Measures

Name	Time	Method
Mini RQLQ (rhino-conjunctivitis quality of life questionnaire) <br/ ><br>VAS (Visual analog scale)Timepoint: 0,4,8, and 12 weeks